Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma

Table 4 Prognostic factors for alpha fetoprotein response n (%)

Prognostic factors	Univariate analysis			Multivariate analysis
	AFP		P value	Odds ratio	95%CI	P value
	Decrease	Increase
Gender			0.478
Female	4 (44)	5 (56)
Male	26 (59)	18 (41)
Age (yr)			< 0.001
< 70	11 (37)	19 (63)
≥ 70	19 (83)	4 (17)		0.116	0.029-0.460	0.002
AFP (ng/mL)			0.570
< 400	20 (61)	13 (39)
≥ 400	10 (50)	10 (50)
BCLC			1.000
Advanced	27 (57)	20 (43)
Terminal	3 (50)	3 (50)
Child-Pugh			0.151
< 7	22 (65)	12 (35)
≥ 7	8 (42)	11 (58)
Diameter (mm)			0.054
< 30	11 (42)	15 (58)
≥ 30	19 (70)	8 (30)		0.286	0.073-1.120	0.072
Dose (Gy)			0.013
< 30	18 (46)	21 (54)
≥ 30	12 (86)	2 (14)		0.992	0.093-10.50	0.995
Dose/fraction (Gy)			0.555
< 8	11 (65)	6 (35)
≥ 8	19 (53)	17 (47)
Lesion			0.270
Intrahepatic	7 (78)	2 (22)
Extrahepatic	23 (52)	21 (48)
Fiducial			0.025
(-)	19 (48)	21 (52)
(+)	11 (85)	2 (15)		0.152	0.026-0.887	0.036
Sorafenib			0.738
(-)	23 (55)	19 (45)
(+)	7 (64)	4 (36)

Fisher's exact test and a logistic regression model were used to evaluate prognostic factors for AFP response. AFP: Alpha fetoprotein.